Recent Press Releases

Johnson & Johnson to Host Medical Devices & Diagnostics Business Review

NEW BRUNSWICK, N.J., April 23, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of i

Allergan Adopts One-Year Stockholder Rights Plan

Allergan Adopts One-Year Stockholder Rights Plan IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that its Board of...

Groups Urge Vermont Governor To Broaden Zohydro Rules

Groups Urge Vermont Governor To Broaden Zohydro Rules National organizations push for 'more thorough approach' to drug abuse epidemic. WASHINGTON, April 23, 2014 /PRNewswire/ -- Today, the...

BIOGEN IDEC FIRST QUARTER 2014 REVENUES REACH $2.1 BILLION DRIVEN BY CONTINUED STRENGTH OF MS FRANCHISE

BIOGEN IDEC FIRST QUARTER 2014 REVENUES REACH $2.1 BILLION DRIVEN BY CONTINUED STRENGTH OF MS FRANCHISE Wednesday, April 23, 2014 7:00 am EDT Quarter Highlighted by EU Approval of TECFIDERA® and...

Gilead Sciences Announces First Quarter 2014 Financial Results

Gilead Sciences Announces First Quarter 2014 Financial Results - Product Sales of $4.87 billion - - Sovaldi Sales of $2.27 billion - - Non-GAAP EPS of $1.48 per share - - Reiterates Full Year...

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion

2014 Revenue and Adjusted EPS Guidance Reaffirmed

THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion 2014 Revenue and Adjusted EPS Guidance Reaffirmed THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN)...

Merck among NASA Cargo Launching to Space Station

Merck among NASA Cargo Launching to Spa​ce Station When the SpaceX-3 cargo resupply mission launched to the International Space Station April 14, an experiment designed by Merck Research Laboratories...

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics Acquires GSK oncology products,...

FDA approves Cyramza for stomach cancer

FDA approves Cyramza for stomach cancer The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction...

GSK announces major 3-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

GSK announces major 3-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders GlaxoSmithKline plc (LSE/NYSE:GSK)...

Lilly Announces Agreement to Acquire Novartis Animal Health

- $5.4 billion deal creates world's second-largest animal health company.

INDIANAPOLIS, April 22, 2014

Lilly's CYRAMZA™ (ramucirumab) Becomes First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy

INDIANAPOLIS, April 21, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the

Lupin Appoints Theresa Stevens as Chief Corporate Development Officer

Lupin Appoints Theresa Stevens as Chief Corporate Development Officer Baltimore, April 21, 2014: Pharma major Lupin today announced the appointment of Theresa Stevens as Chief Corporate Development...

Actavis Announces Departure of G. Frederick Wilkinson, President, Actavis Global R&D

Actavis Announces Departure of G. Frederick Wilkinson, President, Actavis Global R&D DUBLIN, April 21, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that G. Frederick Wilkinson,...

Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone®; Clears Legal Hurdle for Mylan to Launch at Market Formation

Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone®; Clears Legal Hurdle for Mylan to Launch at Market Formation PITTSBURGH, April 18, 2014...

GSK announces approval in Canada for Incruse™ Ellipta™ (umeclidinium) as a treatment for COPD

GSK announces approval in Canada for Incruse™ Ellipta™ (umeclidinium) as a treatment for COPD GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Incruse™ Ellipta™...